Objective: To investigate the effect of bevacizumab combined with XELOX chemotherapy in the treatment of patients with colorectal cancer and its effect on serum CRP levels. Methods: From April 2018 to April 2020 in our hospital, 86 patients with colorectal cancer were divided into groups according to the computerized method and divided into control group 43 cases, treated with XELOX (Oxaliplatin and Capecitabine) regimen, 43 cases in observation group combined with Bevac on the basis of control group.There are 3 cycles of chemotherapy in total and repeated every 3 weeks. The treatment effect and serum levels of the two groups were observed for the treatment with lizumab. Results: The effective rate of the experimental group was 48.83 % (21/43), and the total effective rate of the experimental group was 32.56 % (14/43), which was significantly higher than that of the control group (P＜0.05). Before treatment, there was no significant difference in the serum CRP level between the experimental group and the control group (17.51±3.82 vs. 17.38 ± 3.63, P＞0.05). After treatment, the serum CRP level of the experimental group was significantly lower than that of the control group (7.66±0.71 vs. 11.56±2.32, P＜0.05). The data difference was statistically significant, and there was no significant difference in the incidence of adverse reactions between the two groups (P＞0.05). Conclusion: Bevacizumab combined with XELOX chemotherapy in the treatment of colorectal cancer patients can significantly improve the level of inflammation, improve the immune status, so as to improve the treatment effect, and will not significantly increase the adverse reactions.